Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

- Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the ACHIEVE 2/3 trial in patients with genotypes 2 and 3 chronic hepatitis C -

- Patients receiving 900-mcg Albuferon had comparable rates of serious adverse events, severe adverse events and discontinuations due to adverse events, vs. peginterferon alfa-2a -

ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Albuferon(R) (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 2/3, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C (p=0.0086). Albinterferon alfa-2b is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"We are pleased that Albuferon met its primary endpoint in the ACHIEVE 2/3 trial. These Phase 3 data show that the efficacy of Albuferon was comparable to Pegasys, with half the injections," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We look forward to having the results of ACHIEVE 1, our other Phase 3 trial of Albuferon, in March 2009. If ACHIEVE 1 is successful, we believe Albuferon could become the market-leading interferon for the treatment of chronic hepatitis C, and we expect that global marketing applications will be filed by fall 2009."

David Nelson, M.D., Professor of Medicine, Medical Director of Liver Transplantation, and Chief of the Hepatobiliary Disease Section,
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Dr. Ingrid Warmuth and Anamaria Newport, MHS, PA-C, with locations ... an Open House at their Swedesboro location, 95 Woodstown Road. ... 10 AM to 2 PM. , During the open ... be on hand to talk to people about the benefits ... cosmetic consultations. There will also be specials offered, such as ...
(Date:5/24/2013)... 2013 Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients, ... Ph.D., the Company,s Vice President, Biology and ... Corporate Communications, will present an overview of Senomyx,s technology ... Eastern Time (7:25 a.m. Pacific Time) during the Citi ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a ... research and development, sales and marketing of premium ... today that it is awarding exclusive Vestiage territories ... Reluma Skin Illuminating Facial Care. Qualified applicants can ... an email to info(at)vestiageinc(dot)com and putting RELUMA in ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... AstraZeneca Exec to Lead Hong Kong-based subsidiary Pangu BioPharmaSAN ... biopharmaceutical company focused on discovery and development of an ... multiple disease indications, today announced that Dr. James Cai ... Clinical Development at aTyr Pharma and President of Pangu ...
... & Sullivan recognizes BioTrove, Inc. with the 2009 ... Strategy Leadership of the Year. The annual ... most significant drug-discovery innovations and acknowledgments by life ... specializing in drug acceleration and pipeline assessment technologies, ...
... One Corporation (Pink Sheets: MNCN), announced today that its ... serve as the company,s Chief Financial Officer, effective March ... said, "Pat brings a strong background in finance to ... financial expertise will be great assets to Mach One ...
Cached Biology Technology:Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia 2Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia 3Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies 2Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies 3Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies 4Mach One Announces Appointment of Chief Financial Officer 2
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
(Date:5/22/2013)... cell powered buses, including a team from Simon ... processes and bus membrane durability. , The team ... in the operating cycle of the bus on ... study, led by SFU graduate student Natalia MaCauley, ... Burnaby-based Ballard Power Systems and funded by Automotive ...
(Date:5/22/2013)... The discovery of potential environmental and human health ... batteries each year has led scientists to recommend ... reuse of lithium-ion (Li-ion) battery materials. That,s the ... journal Environmental Science & Technology . , ... Li-ion batteries have become mainstays for powering everything ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2Tests lead to doubling of fuel cell life 2
... counters prevailing thought, a study in mice has found ... "fat-burning" can actually increase energy expenditure and help lower ... the JBC, might lead to some new ... warm-blooded animals need to continually "burn fat" in order ...
... filling such an important niche in ocean communities that ... however, that sea otters can have even farther-reaching effects ... of another top predator: the bald eagle. ... of 250 feet and function much like trees in ...
... 2008) To help improve the success of oyster ... Center for Environmental Science researcher Dr. Elizabeth North is ... study to determine when oysters spawn and where their ... is supported by a $750,000 competitive grant from the ...
Cached Biology News:Making metabolism more inefficient can reduce obesity 2Decline in Alaskan sea otters affects bald eagles' diet 2Decline in Alaskan sea otters affects bald eagles' diet 3
Rat Hepatocytes (RH) (>3,000,000 cells)...
... of proteomics demands the detection of very ... of the AXIMA-CFRplus with improved resolution (20,000) ... provides increased confidence in protein identification. The ... sensitivity, automated sample target handling and the ...
...
... The new MALDI O-TOF creates a ... on an orthogonal platform that has been ... the University of Manitoba. , As the ... orthogonal design and collisional cooling, the prOTOF ...
Biology Products: